847 related articles for article (PubMed ID: 26194676)
21. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A
J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
23. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Watanabe S; Kuwabara Y; Suehiro S; Yamashita D; Tanaka M; Tanaka A; Ohue S; Araki H
Eur J Clin Pharmacol; 2017 Mar; 73(3):357-363. PubMed ID: 27889835
[TBL] [Abstract][Full Text] [Related]
24. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
25. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Happold C; Gorlia T; Chinot O; Gilbert MR; Nabors LB; Wick W; Pugh SL; Hegi M; Cloughesy T; Roth P; Reardon DA; Perry JR; Mehta MP; Stupp R; Weller M
J Clin Oncol; 2016 Mar; 34(7):731-9. PubMed ID: 26786929
[TBL] [Abstract][Full Text] [Related]
26. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Guckenberger M; Mayer M; Buttmann M; Vince GH; Sweeney RA; Flentje M
Strahlenther Onkol; 2011 Sep; 187(9):548-54. PubMed ID: 21858417
[TBL] [Abstract][Full Text] [Related]
27. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
28. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
29. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Hosein AN; Lim YC; Day B; Stringer B; Rose S; Head R; Cosgrove L; Sminia P; Fay M; Martin JH
J Neurooncol; 2015 Apr; 122(2):263-71. PubMed ID: 25648357
[TBL] [Abstract][Full Text] [Related]
30. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
32. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
[TBL] [Abstract][Full Text] [Related]
33. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
35. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
36. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA
J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006
[TBL] [Abstract][Full Text] [Related]
37. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J
J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758
[TBL] [Abstract][Full Text] [Related]
38. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Weller M; Gorlia T; Cairncross JG; van den Bent MJ; Mason W; Belanger K; Brandes AA; Bogdahn U; Macdonald DR; Forsyth P; Rossetti AO; Lacombe D; Mirimanoff RO; Vecht CJ; Stupp R
Neurology; 2011 Sep; 77(12):1156-64. PubMed ID: 21880994
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]